

Workgroup Member Affiliations and Disclosures

Using ICMJE form collection, disclosures are for the past 36 months.

Maria C. Carrillo is a full-time employee of the Alzheimer's Association and has a daughter in the neuroscience program at USC. She has no financial conflicts to disclose.

Heather Snyder is a full-time employee of the Alzheimer's Association, Chicago, IL and has a spouse who is employed by Abbott in an unrelated area. She has no financial conflicts to disclose.

Jeffrey Scott Andrews is employed by Takeda Pharmaceuticals and is a minor shareholder for the company. He has a leadership or fiduciary role in AD PACE Executive Steering Committee and UsAgainstAlzheimer's – Clinical Meaningfulness Forum. He is a former employee of Eli Lilly and Company and is a minor shareholder for the company.

Thomas G. Beach is employed by Banner Health. He has received grant funding from the National Institutes of Health, Veterans Administration, State of Arizona, Life Molecular Imaging, Michael J. Fox Foundation for Parkinson's Research, Avid Radiopharmaceuticals/Eli Lilly, and Gates Foundation. He has received consulting fees from Aprinoia Therapeutics, Biogen MA, and Acadia Pharmaceuticals. He has received payment or honoraria from the World PD Coalition, Mayo Clinic Florida, Stanford University and the IOS Press-Journal of Parkinson's Disease and support for attending meetings from the Alzheimer's Association, AD/PD/Kenes Group, Mayo Clinic Florida and the Universitätsklinikum Hamburg-Eppendorf. He also has a leadership/fiduciary role and stock options with Vivid Genomics.

Teresa Burracchio is employed by the U.S. Food and Drug Administration and has no financial conflicts to disclose.

Billy Dunn is a consultant and has received consulting fees for his role as an advisor for Arch Venture Partners, Cerveau Technologies, Epilepsy Foundation, F-PRIME Capital, Loulou Foundation, and Michael J. Fox Foundation. He has a leadership or fiduciary role in the Virginia Neurological Society (past president) and Prothena Inc. (Director). He holds stock options with Prothena Inc.

Ana Graf is employed by Novartis Pharma AG and has stock options in the company.

Oskar Hansson is employed by Lund University. He has grants or contracts from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. He also has been paid consulting fees by AC Immune, Amylyx, Alzpath, BioArctic, Biogen,

Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens.

Carole Ho is employed by Denali Therapeutics. She has stock options with Denali Therapeutics. Carole is also a Board Director for Beam Therapeutics and NGM Therapeutics and has stock options with both companies.

Clifford R. Jack Jr. is employed by Mayo Clinic. He receives grant funding from the National Institutes of Health, the Alexander family professorship, and the GHR Foundation. Within the past 36 months, he served on a DSMB for Roche pro bono; no payments to the individual or institution were involved. He has received funding from the Alzheimer's Association for travel. In addition, he holds index funds.

William Jagust is employed by University of California, Berkley and has received grants or contracts paid to his institution from the National Institute on Aging, Roche/Genentech, Alzheimer's Association, and BrightFocus Foundation. He has received consulting fees from Biogen, Clario, Eisai, Lilly, and Prothena and has stock with Optoceutics and Molecular Medicine.

Eliezer Masliah* is employed by National Institute on Aging at the National Institutes of Health and has no financial conflicts to disclose.

Eric McDade is employed by Washington University, St Louis and has received grant funding from NIA, Eli Lilly, Hoffmann-La Roche, and the Alzheimer's Association, all directly to his institution. He has received royalties for work on "Methods of diagnosing AD with phosphorylation changes" which is licensed to C2N with royalties to himself and Washington University. He has received consulting fees from Alzamend (SAB member), Sanofi, AstraZeneca, Roche, Grifols, and Sage. He has also received payments from Neurology Live, Kaplan-Projects in Knowledge, and support for travel from Foundation Alzheimer, Alzheimer's Association, and Eisai. He has a patent planned, issued, or pending on "Methods of diagnosing AD with phosphorylation changes" and has participated on a Data Safety Monitoring Board or Advisory Board for Alector and Eli Lilly, both roles for which he was paid. He has a leadership/fiduciary role in Alzamend (paid).

José Luis Molinuevo is a full-time employee of H. Lundbeck A/S. He has received consulting fees from Oryzon, Novo Nordisk, Roche Diagnostics, and Biogen.

Ozioma Okonkwo is employed by University of Wisconsin School of Medicine & Public Health and has received support from the following grants, paid to his institution: R01AG062167, R01AG077507, U19AG024904, U19AG078109, U19AG073153, R01AG066203, R01AG070028, R01AG027161, RF1AG052324. He has received consulting fees from Mayo Clinic Rochester and IUPUI, and holds a leadership or fiduciary role in the International Neuropsychological Society (Board Member) and previously held an advisory role for Society for Black Neuropsychology.

Luca Pani is employed by the University of Miami and the University of Modena and Reggio Emilia and has no financial conflicts to disclose. In unrelated areas, he holds options/stocks from Relmada Therapeutics (US) and NetraMark (Canada).

Michael Rafii is employed by University of Southern California and the Alzheimer's Therapeutics Research Institute (ATRI) and has received grants or contracts from Eisai (AHEAD Study) and Eli Lilly (A4 Study), which were paid to his institution. He has received consulting fees from AC Immune and Ionis. He has participated on a Data Safety Monitoring Board or Advisory Board for Alzheon, Aptah Bio, Biohaven, Embic, Keystone Bio, Prescient Imaging and Positriago.

Laurie Ryan* is employed by National Institute on Aging at the National Institutes of Health and has no financial conflicts to disclose.

Philip Scheltens is employed by Life Science Partners and is Professor Emeritus Amsterdam University Medical Center. He has received grants or contracts from Novo Nordisk, Toyama, UCB, AC Immune, and Alzheon, all paid to his institution. He has an unpaid leadership position as Chair of World Dementia Council, both unpaid. He holds stock options in EQT AB.

Eric Siemers is employed by Acumen Pharmaceuticals, Inc. He has received consulting fees from Biogen Inc., Cogstate Ltd., Cortexyme Inc., Partner Therapeutics Inc., Pinteon Therapeutics Inc., Prothena Inc, Vaccinex Inc., Acumen, Pharmaceuticals Inc., Gates Ventures LLC, and Hoffman La Roche Ltd and payments were made to Siemers Integration LLC. He has participated on a Data Safety Monitoring Board for Hoffman La Roche Ltd. and has had a leadership or fiduciary role with the Alzheimer's Association and BrightFocus Foundation, both unpaid. He holds stock options and is a shareholder for Acumen Pharmaceuticals, and is a shareholder for Eli Lilly and Company.

Reisa Sperling is employed by Brigham and Women's Hospital. She has received grants or contracts from National Institute on Aging, Eli Lilly, Eisai, Alzheimer's Association and GHR Foundation. She has received consulting fees from Abbvie, AC Immune, Acumen, Alector, Alnylam, Bristol-Myers Squibb, Cytos, Genentech, Ionis, Janssen, NervGen, Neuraly, Neurocentria, Oligomerix, Prothena, Roche, Shionogi, and Vaxxinity.

Charlotte E. Teunissen is employed by Amsterdam UMC. She has grants or contracts for Research of the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking (JU), grant No. 101034344) and JPND (bPRIDE), National MS Society (Progressive MS alliance), Alzheimer Drug Discovery Foundation, Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), including TAP-dementia, a ZonMw funded project (#10510032120003) in the context of the Dutch National Dementia Strategy, Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. She is recipient of ABOARD, which is a public-private

partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). She is also a contract researcher for ADx Neurosciences, AC-Immune, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Siemens, Toyama, Vivoryon, and the European Commission. She has received payment or honoraria from Eli Lilly, Grifols, Novo Nordisk, Olink, and Roche, where all payments were made to her institution. She also serves on editorial boards of *Medidact Neurologie/Springer*; and in *Neurology: Neuroimmunology & Neuroinflammation*. She is editor of *Alzheimer Research and Therapy*.

* Advisory member of the workgroup.